Tuesday , January 18 2022
Home / The Capital Spectator / Macro Briefing: 29 November 2021

Macro Briefing: 29 November 2021

Summary:
* Will vaccines stop Omicron? Scientists are looking for the answer* Omicron Covid variant symptoms described as ‘extremely mild’* Omicron variant vaccine could be ready in early 2022, says Moderna* Global markets set for anxious week of digesting Omicron news* No deal in sight as US nears Dec. 15 deadline to raise debt limit* US Dollar Index fell from 16-month high on Friday:

Topics:
James Picerno considers the following as important:

This could be interesting, too:

Gregor Samsa writes The Nonfarm Payrolls Report In Four Charts – Part 1

Gregor Samsa writes Tweet Of The Day: Pity The Penguins

Gregor Samsa writes Cheerleading: The Most Dangerous College Sport?

James Picerno writes 10-Year Treasury Yield ‘Fair Value’ Estimate: 7 January 2022

* Will vaccines stop Omicron? Scientists are looking for the answer
* Omicron Covid variant symptoms described as ‘extremely mild’
* Omicron variant vaccine could be ready in early 2022, says Moderna
* Global markets set for anxious week of digesting Omicron news
* No deal in sight as US nears Dec. 15 deadline to raise debt limit
* US Dollar Index fell from 16-month high on Friday:

Macro Briefing: 29 November 2021

James Picerno
James Picerno is a financial journalist who has been writing about finance and investment theory for more than twenty years. He writes for trade magazines read by financial professionals and financial advisers. Over the years, he’s written for the Wall Street Journal, Barron’s, Bloomberg Markets, Mutual Funds, Modern Maturity, Investment Advisor, Reuters, and his popular finance blog, The CapitalSpectator.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.